Complex cytokine profiles induced by BCG vaccination in UK infants

Vaccine

Volumn 28, Issue 6, 2010, Pages 1635-1641

  Lalor, Maeve K ^a   Smith, Steven G ^a   Floyd, Sian ^a   Gorak Stolinska, Patricia ^a   Weir, Rosemary E ^a   Blitz, Rose ^a   Branson, Keith ^a   Fine, Paul E ^a   Dockrell, Hazel M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

BCG vaccination; Cytokines; Infant immune response

Indexed keywords

BCG VACCINE; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA;

ARTICLE; BCG VACCINATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFANT; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TH17 CELL; TUBERCULOSIS; UNITED KINGDOM;

BCG VACCINE; CELLS, CULTURED; CYTOKINES; GREAT BRITAIN; HUMANS; INFANT; LEUKOCYTES, MONONUCLEAR; MYCOBACTERIUM TUBERCULOSIS;

EID: 75249086006     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.11.004     Document Type: Article

References (40)

1. World Health Organisation. Immunization, surveillance, assessment and monitoring. Reported estimates of BCG coverage; updated 16 December 2008, http://www.who.int/vaccines/globalsummary/immunization/timeseries/tscoveragebcg.htm [accessed 08.05.09].
2. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 8986 (1995) 1339-1345
3. Rodrigues L.C., Diwan V.K., and Wheeler J.G. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 22 6 (1993) 1154-1158
4. Gupta U.D., Katoch V.M., and McMurray D.N. Current status of TB vaccines. Vaccine 25 19 (2007) 3742-3751
5. Kaufmann S.H., and Parida S.K. Tuberculosis in Africa: learning from pathogenesis for biomarker identification. Cell Host Microbe 4 3 (2008) 219-228
6. Lalor M.K., Ben-Smith A., Gorak-Stolinska P., Weir R.E., Floyd S., Blitz R., et al. Population differences in immune responses to Bacille Calmette-Guerin vaccination in infancy. J Infect Dis 199 6 (2009) 795-800
7. Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., and Bloom B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178 6 (1993) 2249-2254
8. Cooper A.M., Dalton D.K., Stewart T.A., Griffin J.P., Russell D.G., and Orme I.M. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178 6 (1993) 2243-2247
9. Newport M., Huxley C.M., and Huston S. A mutation in the interferon gamma receptor gene and susceptibility to mycobacterial infection. New Engl J Med 335 (1996) 1941-1949
10. Black G.F., Weir R.E., Floyd S., Bliss L., Warndorff D.K., Crampin A.C., et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 359 9315 (2002) 1393-1401
11. Weir R.E., Gorak-Stolinska P., Floyd S., Lalor M.K., Stenson S., Branson K., et al. Persistence of the immune response induced by BCG vaccination. BMC Infect Dis 8 (2008) 9
12. Bellamy R., Ruwende C., Corrah T., McAdam K.P., Whittle H.C., and Hill A.V. Assessment of the interleukin 1 gene cluster and other candidate gene polymorphisms in host susceptibility to tuberculosis. Tuber Lung Dis 79 2 (1998) 83-89
13. Hussain R., Kaleem A., Shahid F., Dojki M., Jamil B., Mehmood H., et al. Cytokine profiles using whole-blood assays can discriminate between tuberculosis patients and healthy endemic controls in a BCG-vaccinated population. J Immunol Methods 264 1-2 (2002) 95-108
14. Djoba Siawaya J.F., Beyers N., van Helden P., and Walzl G. Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. Clin Exp Immunol (2009)
15. Sussman G., and Wadee A.A. Supernatants derived from CD8+ lymphocytes activated by mycobacterial fractions inhibit cytokine production. The role of interleukin-6. Biotherapy 4 2 (1992) 87-95
16. Harrington L.E., Mangan P.R., and Weaver C.T. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 18 3 (2006) 349-356
17. Nakae S., Saijo S., Horai R., Sudo K., Mori S., and Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 100 10 (2003) 5986-5990
18. Nakae S., Komiyama Y., Nambu A., Sudo K., Iwase M., Homma I., et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17 3 (2002) 375-387
19. Ishigame H., Nakajima A., Saijo S., Komiyama Y., Nambu A., Matsuki T., et al. The role of TNFalpha and IL-17 in the development of excess IL-1 signaling-induced inflammatory diseases in IL-1 receptor antagonist-deficient mice. Ernst Schering Res Found Workshop 56 (2006) 129-153
20. Khader S.A., and Cooper A.M. IL-23 and IL-17 in tuberculosis. Cytokine 41 2 (2008) 79-83
21. Khader S.A., Bell G.K., Pearl J.E., Fountain J.J., Rangel-Moreno J., Cilley G.E., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8 4 (2007) 369-377
22. Umemura M., Yahagi A., Hamada S., Begum M.D., Watanabe H., Kawakami K., et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis Bacille Calmette-Guerin infection. J Immunol 178 6 (2007) 3786-3796
23. Sutherland J.S., Adetifa I.M., Hill P.C., Adegbola R.A., and Ota M.O. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur J Immunol 39 3 (2009) 723-729
24. Pasquinelli V., Townsend J.C., Jurado J.O., Alvarez I.B., Quiroga M.F., Barnes P.F., et al. IFN-gamma production during active tuberculosis is regulated by mechanisms that involve IL-17, SLAM, and CREB. J Infect Dis 199 5 (2009) 661-665
25. Scriba T.J., Kalsdorf B., Abrahams D.A., Isaacs F., Hofmeister J., Black G., et al. Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 180 3 (2008) 1962-1970
26. Rook G.A., Dheda K., and Zumla A. Immune systems in developed and developing countries; implications for the design of vaccines that will work where BCG does not. Tuberculosis (Edinb) 86 3-4 (2006) 152-162
27. Seah G.T., Scott G.M., and Rook G.A. Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. J Infect Dis 181 1 (2000) 385-389
28. Smith S.M., Klein M.R., Malin A.S., Sillah J., McAdam K.P., and Dockrell H.M. Decreased IFN- gamma and increased IL-4 production by human CD8(+) T cells in response to Mycobacterium tuberculosis in tuberculosis patients. Tuberculosis (Edinb) 82 1 (2002) 7-13
29. Surcel H.M., Troye-Blomberg M., Paulie S., Andersson G., Moreno C., Pasvol G., et al. Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 81 2 (1994) 171-176
30. Ordway D.J., Costa L., Martins M., Silveira H., Amaral L., Arroz M.J., et al. Increased Interleukin-4 production by CD8 and gammadelta T cells in health-care workers is associated with the subsequent development of active tuberculosis. J Infect Dis 190 4 (2004) 756-766
31. North R.J. Mice incapable of making IL-4 or IL-10 display normal resistance to infection with Mycobacterium tuberculosis. Clin Exp Immunol 113 1 (1998) 55-58
32. Rook G.A., Hernandez-Pando R., Dheda K., and Teng Seah G. IL-4 in tuberculosis: implications for vaccine design. Trends Immunol 25 9 (2004) 483-488
33. Del Prete G., De Carli M., Almerigogna F., Giudizi M.G., Biagiotti R., and Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 150 2 (1993) 353-360
34. O'Garra A., and Vieira P. T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol 7 6 (2007) 425-428
35. Mendez-Samperio P., Trejo A., and Perez A. Mycobacterium bovis bacillus Calmette-Guerin induces CCL5 secretion via the Toll-like receptor 2-NF-kappaB and -Jun N-terminal kinase signaling pathways. Clin Vaccine Immunol 15 2 (2008) 277-283
36. Algood H.M., Lin P.L., and Flynn J.L. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 41 Suppl. 3 (2005) S189-S193
37. Szeliga J., Daniel D.S., Yang C.H., Sever-Chroneos Z., Jagannath C., and Chroneos Z.C. Granulocyte-macrophage colony stimulating factor-mediated innate responses in tuberculosis. Tuberculosis (Edinb) 88 1 (2008) 7-20
38. Ryan A.A., Wozniak T.M., Shklovskaya E., O'Donnell M.A., Fazekas de St Groth B., Britton W.J., et al. Improved protection against disseminated tuberculosis by Mycobacterium bovis Bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs. J Immunol 179 12 (2007) 8418-8424
39. Beveridge N.E., Price D.A., Casazza J.P., Pathan A.A., Sander C.R., Asher T.E., et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 37 11 (2007) 3089-3100
40. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13 7 (2007) 843-850